Evorpacept (ALX148) + Trastuzumab + Paclitaxel + Capecitabine + Eribulin + Gemcitabine + Vinorelbine
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer, Metastatic
Conditions
Breast Cancer, Metastatic
Trial Timeline
Apr 28, 2025 → Dec 1, 2027
NCT ID
NCT07007559About Evorpacept (ALX148) + Trastuzumab + Paclitaxel + Capecitabine + Eribulin + Gemcitabine + Vinorelbine
Evorpacept (ALX148) + Trastuzumab + Paclitaxel + Capecitabine + Eribulin + Gemcitabine + Vinorelbine is a phase 1/2 stage product being developed by ALX Oncology for Breast Cancer, Metastatic. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07007559. Target conditions include Breast Cancer, Metastatic.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer, Metastatic were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
9
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07007559 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Breast Cancer, Metastatic